Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Jan 2;16:256. doi: 10.1038/s41467-024-55572-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 3 — a ASCs were treated with increasing doses of AZD1208 for 6 h. Protein levels were assessed by immunoblotting. mRNA expression was assessed by qPCR. Data are shown as mean ± SD (CTL, n = 6; PIMi 5 µM, n = 4; PIMi 20 µM, n = 5). b ASCs were treated with SSO-PIM for 24 h. mRNA expression was assessed by qPCR. Data are shown as mean ± SD (n = 3). c MMCLs were treated with AZD1208 for 24 h. Protein levels were assessed by immunoblotting. The blot is representative of 2 independent experiments. d TP53 mutational and deletion status in 33 MMCLs identifying three TP53 abnormal (TP53 abn) profiles. Cell lines without abnormalities were classified as wild type (TP53 wt). e shTP53 XG7 cells were treated with AZD1208 for 8 h. Protein expression was assessed by immunoblotting. mRNA expression assessed by qPCR. Data are shown as mean ± SD (TP53, n = 6; PMAIP1, n = 5; DDIT3, n = 4). f Cells were treated with AZD1208 and harvest at different time points. Protein levels were assessed by immunoblotting. All markers were processed on the same gel, except for p-BAD processed on a different gel. The blot is representative of 2 independent experiments. g Cells were treated with AZD1208 for 2 h, followed by thapsigargin for 4 h. Protein levels were assessed by immunoblotting. The blot is representative of 2 independent experiments. h ASCs were pre-treated with ISRIB before adding AZD1208 for 6 h. Protein levels were assessed by immunoblotting. Caspase 3-active ASCs were analyzed by flow cytometry. Data were normalized to the control condition. Data are shown mean ± SD (n = 5). i ASCs were pretreated with ISRIB for 2 h followed by SSO-PIM treatment. Protein levels were assessed by immunoblotting and mRNA expression was assessed by qPCR. Data are mean ± SEM (n = 3). P-values were calculated using one-way ANOVA with Dunnett’s adjustment for (a), and two-way ANOVA with Sidak’s adjustment for (b), (h), and (i), and for (e). “n”, denotes the number of biological replicates. Source data are provided as a Source Data file. ASCs, antibody-secreting cells; PIMi, pan-PIM inhibitor AZD1208; Thapsi, thapsigargin; MMCLs, multiple myeloma cell lines; SSO, splice-switching oligonucleotide.